Titlebook: Handbook of Biologics for Rheumatological Disorders; Neeraj Jain,Lalit Duggal Book 2022 The Editor(s) (if applicable) and The Author(s), u

東西

,Biologics in Behcet’s syndrome,s including the mucosal and epithelial barriers of the orogenital apparatus, blood vessels, eyes as well as relatively devastating effects in the brainstem and pulmonary vasculature. The mucocutaneous manifestations of oral and genital ulcers resemble autoinflammatory disorders and are associated wi

CURL

同音

Biologics in Interstitial Lung Diseases in Rheumatological Disorders,oimmune rheumatic diseases (SARDs). Biologic disease modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of various SARDs. Because of the inflammatory nature of ILD, bDMARDs have also been tried in its treatment. No formal guidelines exist on the use of bDMARDs in the treatme

貿(mào)易

Biologics in Osteoporosis, With increasing longevity the burden of this condition worldwide is exponentially rising. Our increasing understanding of bone biology with insights into physiology, function and signalling network between osteoclasts, osteoblasts and osteocytes has paved the way for identification of newer therape

鉆孔

itinerary

Biologics in Juvenile Idiopathic Arthritis,y, synthetic disease modifying agents have been used with varying degrees of clinical improvement. The development of biologics has revolutionized the treatment of JIA. These therapies are often more efficacious and have proven to be of significant benefit in children with refractory arthritis. Thes

調(diào)整校對(duì)

Biologics in Pediatric Connective Tissue Disorders,n priority from saving lives to providing optimum quality of life, especially for children with these chronic diseases. Biologics, particularly Rituximab has been a useful addition in the management of refractory SLE, JDM, and ANCA vasculitis. Although trials of Belimumab in SLE and Infliximab in Ka

證實(shí)

intimate

同來(lái)核對(duì)